XPRIZE Healthspan: What the 10 Finalist Teams Are Testing
Ten research teams just received $1 million each to advance in the XPRIZE Healthspan competition — a $101 million race to find interventions that restore 10 to 20 years of healthy physical and cognitive function in people aged 65 to 80.
Ten research teams just received $1 million each to advance in the XPRIZE Healthspan competition — a $101 million race to find interventions that restore 10 to 20 years of healthy physical and cognitive function in people aged 65 to 80. This is not a supplement company's press release or a longevity influencer's prediction. It is a structured, peer-judged scientific competition with hard outcome targets, and the finalist announcement is the most concrete piece of longevity-research news to land in months. The competition runs through 2030, and what the finalist teams are testing tells you a great deal about where serious aging science actually stands right now — as opposed to where the hype says it is. If you want to understand your own biological age markers in the meantime, Vitals Vault's lab panels and PocketMD advisors can help you build a baseline while this research matures.
Why this is trending
The finalist announcement dropped this week and immediately became the top post in r/longevity, drawing hundreds of comments from people who follow aging research closely. What made it land differently than typical longevity news is the specificity: ten named teams, each with a defined intervention strategy, each now accountable to measurable outcomes in real human participants. That is a higher bar than most longevity studies ever clear. The broader reason this matters is timing. Several converging threads — senolytics, epigenetic reprogramming, GLP-1 research, and immune rejuvenation — have been building for years in separate silos. The XPRIZE structure forces teams to demonstrate results across muscle strength, cognitive performance, and immune function simultaneously, which is genuinely new as a design requirement and reflects a more honest picture of what aging actually does to a body.
What the XPRIZE Healthspan Competition Actually Is
A $101 million prize with hard outcome targets
XPRIZE Healthspan is not a grant program where researchers publish papers and move on. To win, a team must demonstrate that its intervention restores meaningful function — specifically muscle strength, cognitive performance, and immune resilience — in adults aged 65 to 80, with a target of recovering what amounts to 10 to 20 years of biological function. That means the bar is not 'statistically significant improvement on one biomarker' but something closer to 'this person functions like someone a decade or two younger across multiple systems.'
Ten finalist teams, each with $1M to run human trials
The ten teams that advanced each received $1 million to fund the next phase of human testing, which moves the competition from concept into clinical reality. The teams represent a wide range of approaches — from gene therapy and senolytics to lifestyle-based protocols and pharmacological combinations — which means the competition is effectively running parallel experiments on the most promising strategies in aging science right now.
The three pillars judges actually measure
Judging focuses on three domains that map directly to what aging feels like in your body: how strong and mobile you are physically, how well your brain handles memory and processing speed, and how effectively your immune system responds to new threats. Choosing these three is not arbitrary — they are the systems most predictably degraded by aging and most predictably linked to independence, quality of life, and mortality risk.
Lab testing
The XPRIZE teams measure muscle, cognition, and immune markers
you can check your own baseline today
Vitals Vault's starting-from-$99 panel covers 100+ tests in one visit, including inflammatory markers, metabolic health, and more
About 1 week
Schedule online — results typically within a week
Clear next steps
Guidance included, with follow-up care available
HSA / FSA
Eligible for pre-tax health spending accounts
Why This Is Trending Right Now
The longevity community finally has something concrete to discuss
Most longevity news cycles around animal studies, theoretical mechanisms, or supplement claims that never face rigorous human testing. The XPRIZE finalist announcement gave the r/longevity community something rare: named teams, defined interventions, and a timeline with accountability. That specificity is why the post generated so much discussion — people who follow this space closely can now track real progress rather than speculate.
The prize structure itself signals a shift in how aging research is funded
Traditional academic funding rewards publication, not outcomes, which means a study can be considered successful even if the intervention never helps a single person. The XPRIZE model inverts that by paying only for demonstrated results in humans, which attracts teams willing to bet on their own science. That shift in incentive structure is itself news for anyone watching how longevity research gets done.
2030 is close enough to feel real
A competition with a 2030 endpoint means potential winners and their interventions could reach clinical availability within a decade — which puts this within the planning horizon of people in their 40s and 50s today. That proximity makes the science feel personally relevant in a way that 'maybe in 30 years' research does not, and it is a big part of why this announcement resonated beyond the usual research-nerd audience.
What the Finalist Teams Are Testing
Senolytic therapies targeting zombie cells
Several finalist teams are working with senolytics — compounds designed to clear out senescent cells [zombie cells], which are old cells that stop dividing but refuse to die and instead leak inflammatory signals that damage surrounding tissue. The most studied combinations involve dasatinib and quercetin, though some teams are testing newer, more targeted molecules that aim to reduce the collateral effects that come with broader senolytic approaches.
Epigenetic reprogramming to reset cellular age
Some teams are exploring partial epigenetic reprogramming, which uses a subset of the Yamanaka factors — molecular switches that can dial back the biological age of a cell — without fully reverting cells to a stem-cell state, which would be dangerous. The goal is to restore youthful gene expression patterns in aged tissues, particularly in muscle and the nervous system, and early human data is preliminary but has attracted serious scientific attention.
Immune system rejuvenation strategies
Your immune system ages in a process called immunosenescence, where it becomes simultaneously overactive in ways that cause chronic inflammation and underactive in ways that leave you vulnerable to infections and cancer. Finalist teams targeting this domain are testing approaches ranging from thymic regeneration — rebuilding the gland that trains your immune cells — to targeted removal of exhausted immune cells that clog the system without doing useful work.
Multimodal lifestyle and pharmacological protocols
Not every finalist team is working with cutting-edge biotechnology. Some are testing rigorously structured combinations of exercise prescription, nutritional intervention, and established medications — including drugs like metformin or rapamycin — delivered with a precision and consistency that typical lifestyle studies never achieve. These teams are essentially asking whether the gap between 'we know these things help' and 'we can actually make them work reliably in older adults' can be closed with better protocols.
How the Competition Judges Success
Function over biomarkers — a meaningful distinction
A lot of longevity research optimizes for biomarkers: lower inflammation scores, better epigenetic clock readings, improved metabolic panels. The XPRIZE judging criteria require functional outcomes — can you grip harder, walk faster, remember more, fight off an immune challenge better? That distinction matters because a treatment can improve a biomarker without making you feel or function any differently, and the competition is explicitly designed to avoid rewarding that.
Participants must be 65 to 80 — not young and already healthy
Many longevity interventions look impressive in young, healthy volunteers or in people who were already optimizing their health before the study began. The XPRIZE requires results in adults who are actually experiencing age-related decline, which is a much harder test and a much more meaningful one for the people who would eventually use these treatments.
The 2030 final judging and what a winner might look like
By 2030, the grand prize goes to the team that demonstrates the largest, most consistent restoration of function across all three domains in its trial population. A winning intervention might be a single drug, a combination protocol, or a personalized approach that adapts to an individual's biological profile — and the winning team's methods would likely move quickly toward regulatory review and broader clinical availability.
Risks and Honest Caveats
Competition results are not the same as approved treatments
Even if a team wins in 2030, that does not mean the intervention will be available to you in 2031. Regulatory approval, manufacturing scale-up, and insurance coverage all take additional years, and some winning approaches may prove difficult to deliver safely outside a controlled trial setting. Following this competition is genuinely exciting, but it is worth keeping that timeline realistic.
Some approaches carry real biological risks at this stage
Epigenetic reprogramming and senolytic therapies are not things to self-experiment with based on longevity podcast recommendations. Partial reprogramming gone wrong can promote tumor growth, and senolytic drugs like dasatinib are chemotherapy agents with significant side-effect profiles. The reason these are being tested in structured trials with careful oversight is precisely because the risk-benefit calculation is still being worked out.
What you can actually do right now is not nothing
The lifestyle and exercise components that several finalist teams are studying — resistance training, metabolic health optimization, sleep quality, and inflammatory load reduction — are not waiting for a 2030 prize to be validated. The evidence base for these is already strong. Getting a clear picture of your current inflammatory markers, metabolic function, and muscle health gives you a real foundation to work from while the more advanced interventions mature.
Frequently Asked Questions
What is the XPRIZE Healthspan competition trying to prove?
It is trying to prove that a specific intervention can restore 10 to 20 years of healthy function — in terms of muscle strength, cognitive performance, and immune health — in adults aged 65 to 80. The competition requires demonstrated results in real human participants, not just promising lab data or biomarker improvements, which makes it a more rigorous test than most longevity research ever faces.
Who are the 10 finalist teams in the XPRIZE Healthspan competition?
The ten finalist teams represent a range of approaches including senolytics, epigenetic reprogramming, immune rejuvenation, and structured multimodal lifestyle protocols. Each team received $1 million to fund the next phase of human trials. The full list of teams and their specific institutional affiliations is published on the XPRIZE website and has been widely discussed in the longevity research community.
Can I try any of the XPRIZE longevity interventions now?
Some components — particularly the lifestyle, exercise, and metabolic optimization strategies that several teams are studying — are already supported by strong evidence and available to you today. The more advanced approaches like epigenetic reprogramming and novel senolytics are still in clinical trial phases and are not appropriate for self-experimentation, both because the safety profiles are still being established and because the delivery methods require medical supervision.
How is XPRIZE Healthspan different from regular longevity research funding?
Traditional research funding rewards publication and process, meaning a study can be considered successful even if the intervention never demonstrably helps anyone. XPRIZE pays only for results — specifically, functional improvements in real older adults across multiple health domains. That outcome-first incentive structure attracts teams that are confident enough in their science to stake their funding on it, which tends to filter for more rigorous approaches.
What biomarkers should I track if I want to follow my own healthspan?
The three domains the XPRIZE judges — physical function, cognitive performance, and immune health — map to trackable markers including grip strength, inflammatory proteins like C-reactive protein and interleukin-6, metabolic indicators like fasting insulin and HbA1c, and immune cell counts. A comprehensive baseline panel gives you a starting point to measure against over time, and a clinician can help you interpret what your numbers actually mean for your personal health trajectory.